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Abstract
Recent years have seen a growing interest in the use of portable monitoring devices for the diagnosis of obstructive 
sleep apnea syndrome. These have the potential to be used in lieu of the more complicated and uncomfortable 
alternative, polysomnography, which has long been considered to be the gold standard for the diagnosis of this 
relatively prevalent condition. Following their approval in 2008 by the Center of Medicare and Medicaid Services, the 
federal agency which administers Medicare and Medicaid in the United States, there has been extensive discussion 
about the utility and validity of these devices for use in the diagnosis of obstructive sleep apnea syndrome. Although 
there are various models of portable monitoring devices, the literature contains little information regarding how 
each device should be used in specific age groups, patients presenting comorbidities, and asymptomatic patients. 
Additionally, studies about the cost-effectiveness of this diagnostic method are scarce and conflicting. Therefore, 
this objective of this study was to review what has been learned about portable monitoring devices over time, as 
well as to examine the recent progress, advantages, limitations, and applications of these devices in the diagnosis 
of obstructive sleep apnea syndrome in different groups of patients. 
Keywords: Sleep apnea, obstructive/diagnosis; Polysomnography; Diagnostic equipment; Monitoring, 
ambulatory.
Resumo
Nos últimos anos, é crescente o interesse pela utilização de aparelhos de monitoramento portáteis para o diagnóstico 
da síndrome da apneia obstrutiva do sono, como uma alternativa mais simples e confortável à polissonografia, que 
é o exame considerado o padrão ouro para o diagnóstico dessa condição relativamente prevalente. A liberação do 
uso desses equipamentos pelo Center of Medicare and Medicaid Services, agência federal que administra os serviços 
médicos nos Estados Unidos da América, em 2008, resultou em ampla discussão sobre a utilidade e validade desses 
equipamentos para o diagnóstico de síndrome da apneia obstrutiva do sono. Apesar de haver vários modelos de 
equipamentos de monitorização portátil, há pouca informação na literatura a respeito de como cada equipamento 
deveria ser utilizado em grupos etários específicos, portadores de comorbidades e pacientes assintomáticos. Além 
disso, estudos de custo-efetividade desse método diagnóstico são escassos e conflitantes. Portanto, o objetivo do 
presente estudo foi revisar a evolução dos conhecimentos no uso de equipamentos de monitorização portátil, bem 
como examinar os avanços recentes, vantagens, limitações e aplicações desses equipamentos para o diagnóstico de 
apneia obstrutiva do sono em diferentes grupos de pacientes. 
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recent, well-designed studies conducted in Brazil 
evaluated the accuracy of in-home recordings 
using PMDs, compared with polysomnography 
recordings made in a sleep laboratory.(29,30)
There has been much discussion surrounding 
the utility, advantages, and limitations of using 
PMDs for the in-home diagnosis of OSAS, 
without the supervision of a trained professional. 
The fact is that the use of such devices not only 
facilitates access to polysomnographic data but 
also improves the quality of the data, since they 
are collected within the comfort of the habitual 
sleep settings, thus aiding in the diagnosis of 
OSAS. Studies conducted in the USA, Brazil, 
and Canada, as well as in a number of other 
countries, have shown the efficacy of in-home 
monitoring in diagnosing OSAS in patients with 
a high suspicion of the syndrome.(31-33)
Here, we review what is known about the 
use of PMDs in the diagnosis of OSAS, including 
recent findings, as well as the advantages 
and limitations of the applications of this 
technology.
Types of monitoring used in the 
diagnosis of OSAS
According to the American Sleep Disorders 
Association (ASDA),(34,35) the methods of 
investigating OSAS can be classified by the type 
of sleep study employed. 
Full-night in-laboratory 
polysomnography: type 1 sleep studies
Full-night polysomnography is used as 
the standard to which other types of sleep 
studies are compared. It records at least seven 
bioparameters, including electroencephalography 
(EEG), chin electromyography (EMG), 
electrooculography (EOG), airflow, respiratory 
effort (measured by recording movements of 
the thorax and abdomen), pulse oximetry, and 
electrocardiography (ECG). The position of the 
body must also be established in an objective 
manner and duly documented. Periodic leg 
movements can be recorded, although this 
is optional. In-laboratory polysomnography 
requires a specialized laboratory, as well as a 
trained professional who intervenes if there is an 
adverse event during the recording. 
Introduction
Obstructive sleep apnea syndrome (OSAS) 
is a highly prevalent condition that is observed 
in 1.2% to 7.5% of the general population,(1-9) 
mostly in adults and primarily in obese males.
(10) The definition of OSAS is an apnea-hypopnea 
index (AHI) above five events per hour of sleep, 
together with excessive daytime sleepiness.(1-10) 
A recent epidemiological study conducted in 
the city of São Paulo, Brazil,(11) showed a high 
prevalence of OSAS in the adult population 
(32.8%).(12) In that study, OSAS was defined 
according to the criteria of the most recent 
International Classification of Sleep Disorders, 
published by the American Academy of Sleep 
Medicine (AASM) in 2005,(13) which state that 
a diagnosis of OSAS can be confirmed if the 
subject has an AHI of 5.0-14.9 events per hour 
of sleep and presents with at least one of the 
following complaints: loud snoring, excessive 
daytime sleepiness, and fatigue. In addition, 
subjects with an AHI equal to or greater than 
15, with or without any additional complaints, 
can be classified as having OSAS. Because of the 
high prevalence of OSAS, it is unlikely that there 
will ever be enough sleep laboratories to screen 
and diagnosis all of the cases. 
There is a well-established association between 
OSAS and excessive daytime sleepiness, which 
leads to traffic accidents,(14-17) as well as between 
OSAS and hypertension.(18) In addition, OSAS is 
a harbinger of the aggravation or the onset of 
heart diseases, such as arrhythmia, coronary 
insufficiency, heart failure, and stroke.(19-24)
Although polysomnography is considered 
the gold standard for the diagnosis of OSAS, 
it is costly and involves a technically complex 
examination.(25) There is some evidence that OSAS 
is underdiagnosed because neither physicians 
nor patients have sufficient information about 
the syndrome. In addition, there are few 
laboratories that specialize in polysomnography.
(26,27) Consequently, in recent decades, there has 
been an increased interest in exploring cost-
effective methods of diagnosing OSAS, and 
greater attention has therefore been focused on 
portable monitoring devices (PMDs).(28)
Although the use of PMDs has been 
proposed for the diagnosis of OSAS, most 
studies attempting to determine the accuracy of 
these devices have not followed the best practice 
guidelines for diagnostic test validation. Two 
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to correct faults that tend to occur during the 
test. Therefore, at that time, the ASDA did 
not recommend the use of PMDs by unstable 
patients, by patients with mild symptoms, for the 
screening of asymptomatic high-risk patients, or 
for the titration of continuous positive airflow 
pressure (CPAP).(34) The supervised use of PMDs 
was indicated for patients with severe symptoms 
of OSAS for whom treatment was urgent and 
for patients who were unable to reach a sleep 
laboratory, as well as for those who had been 
previously diagnosed with OSAS by means of 
polysomnography. However, the use of type 
4 devices was not considered acceptable for the 
assessment of OSAS.(32,33)
In 1997, the ASDA assembled a new task 
force in order to establish the effectiveness of 
polysomnography and related procedures.(36) The 
resulting study revealed that the sensitivity and 
specificity of PMDs for the diagnosis of OSAS 
was lower than was that of polysomnography. 
That study mentioned the need for better 
establishing and validating the bioparameters 
recorded by this kind of equipment. The 
supervised use of type 3 sleep studies continued 
to be indicated for patients in whom there was a 
strong suspicion of OSAS. If the results collected 
from type 3 sleep studies were negative for OSAS 
in asymptomatic patients, the indication for 
complete in-laboratory polysomnography was 
upheld. Type 4 sleep studies continued to be 
contraindicated in such cases. A systematic review 
and meta-analysis of the literature conducted in 
2000 drew the same conclusions.(37)
In 2003, another group of authors(38) assessed 
the effectiveness of PMDs in confirming or 
excluding the diagnosis of OSAS. Type 2 sleep 
studies, whether supervised or unsupervised, 
did not produce any evidence to support 
either function. Supervised type 3 sleep studies 
produced a great deal of evidence to either 
exclude or confirm OSAS, whereas unsupervised 
type 3 sleep studies produced very little. In 
supervised sleep studies, the potential advantage 
of PMDs was a decrease in the time spent by the 
technician and physician when compared with 
polysomnography. The loss of data was also 
assessed, and it was found that there was a 20% 
loss related to type 2 sleep studies,(39) compared 
with 3-18% related to the unsupervised in-home 
use of type 3 sleep studies.(40-42) When supervised 
type 3 sleep studies were performed in a sleep 
laboratory, the loss of data ranged from 3% to 
9%.(43,44) The need for studies examining specific 
Comprehensive in-home 
polysomnography: type 2 sleep studies
Type 2 sleep studies measure the same seven 
bioparameters measured by type 1 devices (EEG, 
chin EMG, EOG, airflow, respiratory effort, 
pulse oximetry, and ECG). Body position can be 
objectively established, and the measurement 
of periodic leg movements is desirable, but 
optional. The examination is not supervised by a 
trained professional.
Modified in-home sleep apnea testing: 
type 3 sleep studies
Type 3 sleep studies record data related to at 
least four bioparameters, including ventilation 
(at least two bioparameters of respiratory 
movement; or respiratory movement and airflow), 
HR or ECG, and pulse oximetry. Monitoring can 
include EMG of the legs, and the presence of a 
trained professional is not required.
Continuous single- or dual-bioparameter 
in-home recording: type 4 sleep studies
Most of the PMDs employed in type 4 sleep 
studies record data related to only one or two 
bioparameters (airflow, pulse oximetry, or both). 
Even sleep studies conducted with devices that 
record three or more bioparameters are classified 
as type 4 studies if the device employed does 
not record airflow. Type 4 sleep studies do not 
require the presence of a trained professional.
Validation of the use of PMDs: 
historical perspective
The first attempts to review and standardize 
the use of PMDs in the diagnosis of OSAS were 
made in 1994 by the ASDA.(34,35) The authors 
concluded that there was no standardization 
of PMDs and that they varied widely in 
complexity, ranging from the recording of only 
one bioparameter to full polysomnography. 
At the time, there had been few studies on 
the topic, and there was little evidence to 
recommend their use over the standard method. 
Although the convenience for the patient, lower 
operational costs, potentially better treatment 
adherence, and increased accessibility were 
considered advantages, the main limitation 
of the unsupervised use of PMDs was their 
unsupervised nature, translating to an inability 
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to immobility or critical conditions of the 
patient.
•	They	 were	 recommended	 as	 a	 way	 to	
monitor the response to treatment with an 
intraoral device (although not for CPAP) or 
to surgical procedures involving the upper 
airways.
•	Their	 use	 was	 considered	 an	 acceptable	
means of monitoring weight loss.
•	They	 were	 approved	 for	 selective	 use	 in	
patients who had OSAS symptoms but no 
comorbidities.
•	Their	use	was	not	considered	acceptable	for	
the diagnosis of other sleep disturbances, 
such as central apnea, periodic leg 
movement, parasomnia, alterations in the 
circadian rhythm, and narcolepsy.
•	They	 were	 not	 recommended	 for	 the	
screening of asymptomatic patients.
Despite the practical recommendations set 
forth by the AASM about the use of PMDs in the 
diagnosis of OSAS, some third-party health care 
companies, such as CIGNA (Philadelphia, PA, 
USA)(47) and Blue Cross of California (Thousand 
Oaks, CA, USA),(48) covered the use of PMDs, but 
only under the specific conditions laid out by 
the AASM. Therefore, the American Academy 
of Otolaryngology – Head and Neck Surgery 
filed a request with the Centers for Medicare 
and Medicaid Services (CMS) asking that the 
CMS reconsider its positions on PMD studies. 
The American College of Chest Physicians, the 
American Thoracic Society, and the AASM, 
all motivated by the previously noted lack of 
evidence to indicate greater efficacy and cost-
effectiveness, coordinated rebuttal arguments to 
dissuade the CMS from altering its position. In 
contrast, a significant number of practitioners, 
the National Sleep Foundation, and Apria Health 
Care (Lake Forest, CA, USA) argued that PMD 
studies would be beneficial in the diagnosis and 
management of OSAS.(49)
In 2007, based on the reports produced by the 
Agency for Healthcare Research and Quality,(50) 
the CMS approved the use of unsupervised 
PMD sleep studies for the diagnosis of OSAS, 
with the objective of determining whether 
treatment with CPAP was warranted.(51) The fully 
accepted PMDs were those capable of producing 
type 2 or 3 sleep studies. Type 4 sleep studies 
were accepted if they recorded at least three 
bioparameters (those that recorded oximetry 
alone were not endorsed). This decision will most 
likely result in a more widespread application of 
PMDs for the purpose of diagnosing OSAS. Still, 
groups, including those with comorbidities 
associated with OSAS, has also been discussed.
In 2003, the AASM(45) published practical 
guidelines for the use of PMDs in the diagnosis of 
OSAS, in which the use of PMDs for the screening 
of OSAS was not recommended in patients 
without symptoms suggestive of the disease. The 
use of PMDs was also not indicated for patients 
with associated comorbidities, such as heart 
failure, lung disease, hypoventilation syndrome, 
and stroke. The indication for the use of PMDs 
was restricted to cases in which patients had 
severe symptoms of OSAS, in which they could 
not be examined in a sleep laboratory, or in which 
there had already been a definitive diagnosis 
of OSAS using polysomnography. In addition, 
manual scoring was determined to be more 
accurate (i.e., automatic scoring was rejected). 
Type 1 sleep studies (full-night in-laboratory 
polysomnography) were recommended for cases 
in which type 3 studies had yielded negative 
results for OSAS in symptomatic patients. Type 
3 sleep studies, whether split-night or full-night, 
were not recommended for CPAP titration. Type 4 
sleep studies continued to be contraindicated for 
OSAS diagnosis. In 2005, the AASM(46) published 
new practical guidelines for the indication 
of polysomnography and related procedures, 
maintaining the recommendations that it had 
put forth in 2003. Those guidelines reiterated the 
statement that if type 3 sleep studies produced 
negative results for OSAS, the patient should 
undergo type 1 sleep studies. However, in 2007, 
the AASM revised its recommendations on the use 
of PMDs in the diagnosis of OSAS, particularly 
with respect to the use of unsupervised type 3 
sleep studies in individuals over 18 years of age 
presenting OSAS symptoms.(25) The standard put 
forth therein was that the sleep studies should, 
at the least, record airflow, respiratory effort, 
oximetry, and HR. Additional recommended uses 
of and contraindications for the use of PMDs 
were as follows: 
•	Their	use	was	considered	acceptable	for	the	
diagnosis of OSAS in patients who are very 
likely to present the syndrome, based on 
a pre-test for OSAS and after a thorough 
clinical assessment.
•	They	should	be	used	in	adult	patients	only,	
since, at the time, there were no related 
studies in children and elderly individuals.
•	Their	 use	 was	 considered	 acceptable	 for	
the diagnosis of OSAS whenever type 1 
sleep studies cannot be performed due 
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predominantly at high risk for OSAS. In addition, 
there are few studies on the use of PMDs for 
the diagnosis of OSAS in women, since they 
normally develop milder forms of the disease or 
are asymptomatic.(52,53)
Despite the validation of some PMDs, there 
is currently no evidence to support the use of 
in-home OSAS screening of children, the elderly, 
or individuals who have comorbidities, such as 
severe lung disease, neuromuscular disease, and 
heart diseases. These groups are of significant 
importance due to the greater difficulty that 
they face in going to a sleep laboratory, and 
further studies will be required in order to assess 
their diagnostic needs.
Cost-effectiveness of the use of PMDs
The analysis of the cost-effectiveness of 
the use of PMDs for the diagnosis of OSAS 
is particularly dependant on clinical studies. 
However, there have been only a few randomized 
clinical trials involving different strategies for the 
diagnosis and treatment of OSAS that include the 
collection of data about quality of life, health, 
and economic aspects.(57-60) One review,(57) using 
a model for the cost-utility analysis, comparing 
laboratory polysomnography, in-home 
monitoring, and no testing for five years after 
the initial evaluation for OSAS, including CPAP 
therapy, involved a hypothetical cohort of 
individuals suspected of having OSAS. Quality of 
life, survival, and charges for (as proxies for costs 
of) each diagnostic method were considered. In 
the five years following the initial diagnostic 
evaluation, polysomnography provided maximal 
quality-adjusted life-years (QALYs). The 
incremental charges for polysomnography over 
in-home monitoring or no testing (in USD) were 
approximately $13,400 and $9,200, respectively, 
per QALY gained during this period. The results 
of that study suggest that the most precise 
and expensive test (polysomnography) not only 
provides better outcomes for patients but also 
represents, from a societal perspective, the 
most cost-effective option relative to in-home 
monitoring and no testing. However, those 
authors also suggested that future studies should 
be aimed at making a more precise determination 
of certain key variables in this model.
One study(59) used a decision-tree model that 
incorporated typical clinical algorithms to evaluate 
split-night polysomnography and in-home 
the advantages and limitations of these devices 
must be considered in order to ensure the most 
accurate results.(52,53)
Limitations to the validation of PMDs
Validation of PMDs makes for a challenging 
task since they are generally compared with 
polysomnography. Despite being held as the gold 
standard, polysomnography also has limitations 
that must be taken into consideration: variability 
of AHI results when the subject is observed over 
different nights or by different observers(54); 
longer time spent in the supine position when 
compared with habitual sleep(31); and difficulty 
in sleeping in an unfamiliar environment.(55) Of 
note, it is relevant to highlight the impact of 
a given polysomnography result on quality of 
life, morbidity, and mortality, since some studies 
have shown that the AHI correlates poorly with 
quality of life and daytime sleepiness, parameters 
that weigh heavily in the management of OSAS 
patients.(38)
Another difficulty that arises when comparing 
polysomnography and PMD results is related 
to the calculation of the rate of abnormal 
breathing events during each kind of recording. 
Traditionally, polysomnography provides the 
average number of breathing events per hour 
of sleep, that is, the calculation is made by 
dividing the total number of breathing events 
by the total sleep time, in hours. In contrast, 
because PMDs do not measure the total sleep 
time, the calculation of the average number 
of abnormal breathing events is based on the 
total recording time, which could underestimate 
the rate of those events when compared with 
polysomnography.(52,53)
When considering the identification of 
breathing events by polysomnography, hypopnea 
is in part scored if associated with EEG arousal or 
oxyhemoglobin desaturation.(56) As PMDs do not 
allow for the assessment of arousal, the number 
of hypopnea events might be underestimated, 
a possibility that impairs the estimation of the 
severity of the disease. 
Several devices that fall under the 
denomination “PMD” require individual 
validation, since they record different numbers 
and types of bioparameters.(52,53) Therefore, there 
should be no generalized conclusion about 
the validity of different devices drawn from 
studies involving only a particular device or a 
particular situation. Studies examining such 
validation often make use of a population that is 
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Final considerations
The current guidelines concerning PMDs 
allow for the use of these devices by patients 
who have no comorbidities and have a high 
pre-test probability of OSAS. Based on the CMS 
recommendations allowing PMDs to be used for 
the diagnosis of OSAS, it is believed that the 
use of in-home monitoring will become more 
widespread. Although various models have been 
introduced to meet this increased demand, each 
device will need to be validated individually. In 
addition, randomized clinical trials examining 
PMDs should be carried out in specific cohorts 
(children, the elderly, females, etc.) and in 
individuals with various comorbidities (such 
as severe lung disease, heart diseases, and 
neuropathy), as well as in patients who are 
asymptomatic or present with only mild OSAS. 
The conclusions and the recommended course 
of action will therefore hinge on the data as 
viewed in relation to the cost-effectiveness 
of in-home monitoring versus in-laboratory 
polysomnography. 
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